Molecular Mechanisms in Skeletal Muscle Underlying Insulin Resistance in Women Who Are Lean With Polycystic Ovary Syndrome

J Clin Endocrinol Metab. 2019 May 1;104(5):1841-1854. doi: 10.1210/jc.2018-01771.

Abstract

Context: Skeletal muscle molecular mechanisms underlying insulin resistance in women with polycystic ovary syndrome (PCOS) are poorly understood.

Objective: To provide insight into mechanisms regulating skeletal muscle insulin resistance in women who are lean with PCOS.

Participants and methods: A hyperinsulinemic-euglycemic clamp with skeletal muscle biopsies was performed. Thirteen women who are lean who have hyperandrogenism and PCOS and seven age- and body mass index-matched healthy control subjects were enrolled. Skeletal muscle protein expression and phosphorylation were analyzed by Western blotting and intramuscular lipid content was measured by thin-layer chromatography.

Results: Women with PCOS had 25% lower whole-body insulin sensitivity and 40% lower plasma adiponectin concentration than in control subjects. Intramuscular triacylglycerol, sn-1.3 diacylglycerol, and ceramide contents in skeletal muscle were higher (40%, 50%, and 300%, respectively) in women with PCOS than in control subjects. Activation of insulin signaling did not differ between groups. In women with PCOS, the insulin-stimulated glucose oxidation was reduced and insulin-stimulated dephosphorylation of pyruvate dehydrogenase (PDH) Ser293 was absent. AMP-activated protein kinase (AMPK) α2 protein expression and basal Thr172 phosphorylation were 45% and 50% lower in women with PCOS than in control subjects, respectively.

Conclusions: Whole-body insulin resistance in women who are lean who have hyperandrogenism and PCOS was not related to changes in the proximal part of the insulin signaling cascade in skeletal muscle despite lipid accumulation. Rather, reduced insulin sensitivity was potentially related to plasma adiponectin levels playing a modulating role in human skeletal muscle via AMPK. Furthermore, abnormal PDH regulation may contribute to reduced whole-body metabolic flexibility and thereby insulin resistance.

Trial registration: ClinicalTrials.gov NCT02429128.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • AMP-Activated Protein Kinases / metabolism
  • Adiponectin / metabolism
  • Adult
  • Biomarkers / metabolism
  • Body Mass Index
  • Case-Control Studies
  • Female
  • Follow-Up Studies
  • Glucose Clamp Technique
  • Humans
  • Hyperandrogenism / physiopathology*
  • Insulin / metabolism*
  • Insulin Resistance*
  • Ketone Oxidoreductases / metabolism
  • Male
  • Muscle, Skeletal / physiopathology*
  • Phosphorylation
  • Polycystic Ovary Syndrome / physiopathology*
  • Prognosis
  • Thinness / physiopathology*

Substances

  • ADIPOQ protein, human
  • Adiponectin
  • Biomarkers
  • Insulin
  • Ketone Oxidoreductases
  • pyruvate dehydrogenase (NADP+)
  • AMP-Activated Protein Kinases

Associated data

  • ClinicalTrials.gov/NCT02429128